Magnus Bergkvist1, Sebastian S Mukka2, Lars Johansson3, Torbjörn E Ahl1, Arkan S Sayed-Noor2, Olof G Sköldenberg1, Thomas Eisler1. 1. Department of Orthopaedics at Danderyd Hospital and Karolinska Institute, Department of Clinical Sciences at Danderyd Hospital (KIDS), Stockholm - Sweden. 2. Department of Surgical and Perioperative Sciences, Umeå University, Umeå - Sweden. 3. Department of Infectious Diseases, Karolinska University Hospital, Stockholm - Sweden.
Abstract
INTRODUCTION: Periprosthetic joint infection (PJI) is a devastating complication in hip arthroplasty surgery. Debridement, antibiotics (AB) and implant retention (DAIR) is recommended in early PJI in association with stable implants. The aim of this study was to evaluate the success rate of DAIR in early PJI (<4 weeks) and to identify factors predicting the outcome. METHODS: This cohort study included a consecutive series of 35 patients (median age 74 years, 25 women, 26 primary arthroplasties) treated with DAIR for an early PJI in a regional hospital. RESULTS: 28 patients (80%) had their infection eradicated. DAIR-only eradicated the PJI in 22 (63%) patients with a median follow-up of 50 (24-84) months. In 17 (49%) patients, oral AB had been given prior to intraoperative cultures, which delayed first debridement with average 6 days and delayed hospital stay. Primary surgery for a hip fracture increased the risk of DAIR-failure. Surgical experience did not affect the outcome. 17% (n = 6) of the patients sustained a secondary infection during their hospital stay; the majority was beta-lactam resistant coagulase negative Staphylococcus aureus. CONCLUSIONS: The success rate of DAIR was inferior to pervious controls from experienced revision centers. Hip fracture patients should be informed about the increased risk of DAIR treatment failure. In order not to delay surgery, empirically based oral AB should not be administered prior to deep cultures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02087020.
INTRODUCTION: Periprosthetic joint infection (PJI) is a devastating complication in hip arthroplasty surgery. Debridement, antibiotics (AB) and implant retention (DAIR) is recommended in early PJI in association with stable implants. The aim of this study was to evaluate the success rate of DAIR in early PJI (<4 weeks) and to identify factors predicting the outcome. METHODS: This cohort study included a consecutive series of 35 patients (median age 74 years, 25 women, 26 primary arthroplasties) treated with DAIR for an early PJI in a regional hospital. RESULTS: 28 patients (80%) had their infection eradicated. DAIR-only eradicated the PJI in 22 (63%) patients with a median follow-up of 50 (24-84) months. In 17 (49%) patients, oral AB had been given prior to intraoperative cultures, which delayed first debridement with average 6 days and delayed hospital stay. Primary surgery for a hip fracture increased the risk of DAIR-failure. Surgical experience did not affect the outcome. 17% (n = 6) of the patients sustained a secondary infection during their hospital stay; the majority was beta-lactam resistant coagulase negative Staphylococcus aureus. CONCLUSIONS: The success rate of DAIR was inferior to pervious controls from experienced revision centers. Hip fracturepatients should be informed about the increased risk of DAIR treatment failure. In order not to delay surgery, empirically based oral AB should not be administered prior to deep cultures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02087020.
Authors: Andreas Mauerer; Stefanie Stenglein; Stefan Schulz-Drost; Christoph Schörner; Dominic Taylor; Sebastian Krinner; Frank Heidenau; Werner Adler; Raimund Forst Journal: Molecules Date: 2017-06-23 Impact factor: 4.411
Authors: Joyce van Eck; Wai-Yan Liu; Jon H M Goosen; Wim H C Rijnen; Babette C van der Zwaard; Petra Heesterbeek; Walter van der Weegen Journal: J Bone Jt Infect Date: 2022-07-06
Authors: Iker Uriarte; Jesús Moreta; Javier Mosquera; María J Legarreta; Urko Aguirre; José L Martínez de Los Mozos Journal: Hip Pelvis Date: 2019-08-29